RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Total cash & short-term investments

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$4B
P/E ratio
SummaryFinancials
Period EndTotal cash & short-term investments (Million USD)YoY (%)
Dec 31, 2024256+50.41%
Dec 31, 2023170-19.62%
Dec 31, 2022212-37.89%
Dec 31, 2021341-17.11%
Dec 31, 2020412-61.56%
Dec 31, 20191,071+48.49%
Dec 31, 2018721+257.53%
Dec 31, 2017202+42.97%
Dec 31, 2016141-29.55%
Dec 31, 2015200+19.65%
Dec 31, 2014167+947.22%
Dec 31, 201316+29.06%
Dec 31, 201212-27.35%
Dec 31, 201117

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)